Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fortinet Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Fortinet Inc trades at $158.82 (market cap $115.40B). The key difference: Fortinet Inc is far larger — about 2.9× Alnylam Pharmaceuticals, Inc.'s market cap, and Fortinet Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FTNT | |
|---|---|---|
Market Cap | $39.89B | $115.40B |
Sector | Health | Technology |
52-Week High | $491.22 | $163.73 |
52-Week Low | $278.09 | $74.39 |
Enterprise Value | $38.15B | $112.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Fortinet (FTNT) trades at $157.51, down 3.8% over the past day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.82 versus $0.619 expected, and maintains robust profitability with a net income margin of 27.49%. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the stock up significantly year-to-date.
The outlook remains positive due to sustained earnings beats and sector tailwinds, but high valuation multiples (P/E of 61.05) and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $117.42 suggests caution relative to the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
